Inhibition of histidine ammonia lyase by 8-methoxypsoralen and psoralen-oxidized photoproducts

Photochem Photobiol. 2010 Nov-Dec;86(6):1272-7. doi: 10.1111/j.1751-1097.2010.00807.x. Epub 2010 Sep 29.

Abstract

The effect of 8-methoxypsoralen-UVA therapy on the catalysis of histidine to trans-urocanic acid by histidine ammonia lyase (HAL, EC 4.3.1.3) was examined using an enzymatic assay from Sigma-Aldrich where the growth of the trans-urocanic acid peak at 277 nm was monitored. A Rayonet Photochemical Mini Reactor (Model RMR-600) equipped with eight, 3500 Å light sources and a custom UVA filter (Model S-BAL3 2.9 mm), from the Solar Light Company, were used to expose various reaction mixtures to broadband UVA light and UVA/UVB light. A UV-Vis spectrophotometer (Model Shimadzu UV 2540) with a temperature-controlled cell holder (Model TCC240) was used to monitor the growth of the trans-urocanic peak. Results of dark-binding experiments of 8-methoxypsoralen in denatured ethanol indicate no inhibition of enzyme activity due to ethanol but noncompetitive inhibition due to 8-methoxypsoralen. The effects of preirradiated 8-methoxypsoralen, with both broadband UVA and UVA/UVB, indicate that inhibition was due to psoralen-oxidized photoproducts. Inhibition of HAL was found when exposed to broadband UVA/UVB and to a lesser extent when exposed to broadband UVA.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Histidine Ammonia-Lyase / antagonists & inhibitors*
  • Humans
  • Immunosuppression Therapy
  • Methoxsalen / pharmacology*
  • Oxidation-Reduction
  • PUVA Therapy
  • Photochemical Processes
  • Photosensitizing Agents / pharmacology
  • Skin Diseases / drug therapy
  • Skin Diseases / enzymology
  • Skin Diseases / immunology
  • Urocanic Acid / metabolism

Substances

  • Photosensitizing Agents
  • Histidine Ammonia-Lyase
  • Urocanic Acid
  • Methoxsalen